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ZEB1 and ZEB2 are structurally related E-box binding homeobox tran-scription factors that induce epithelial to mesenchymal transitionsduring development and disease. As such, they regulate cancer cell
invasion, dissemination and metastasis of solid tumors. In addition, their
expression is associated with the gain of cancer stem cell properties and
resistance to therapy. Using conditional loss-of-function mice, we previous-
ly demonstrated that Zeb2 also plays pivotal roles in hematopoiesis, con-
trolling important cell fate decisions, lineage commitment and fidelity. In
addition, upon Zeb2 overexpression, mice spontaneously develop imma-
ture T-cell lymphoblastic leukemia. Here we show that pre-leukemic Zeb2-
overexpressing thymocytes are characterized by a differentiation delay at
beta-selection due to aberrant activation of the interleukin-7 receptor signal-
ing pathway. Notably, and in contrast to Lmo2-overexpressing thymocytes,
these pre-leukemic Zeb2-overexpressing T-cell progenitors display no
acquired self-renewal properties. Finally, Zeb2 activation in more differenti-
ated T-cell precursor cells can also drive malignant T-cell development, sug-
gesting that the early T-cell differentiation delay is not essential for Zeb2-
mediated leukemic transformation. Altogether, our data suggest that Zeb2
and Lmo2 drive malignant transformation of immature T-cell progenitors
via distinct molecular mechanisms. 
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ABSTRACT
Introduction
T-cell development starts with the migration of bone marrow-derived progenitor
cells into the thymus. There, these newly arrived early T-cell progenitors rapidly
lose their multipotent character and gradually reprogram into the T-cell lineage. T-
cell commitment occurs through an orderly process that is tightly regulated by
interplay between key signaling pathways and transcription factors.1 Once com-
mitted, immature T-cell progenitors undergo successive and dynamic stages of dif-
ferentiation, including positive selection for the T-cell receptor complex in the cor-
tex, as well as negative selection for removal of potential self-responsive cells in the
medulla.2 Alterations in this process can lead to the development of T-cell acute
lymphoblastic leukemia (T-ALL). During malignant transformation, a clonal expan-
sion of immature T cells is selected for via the gradual accumulation of advanta-
geous epigenetic changes and genetic mutations.3,4
E-proteins, E2A and HEB, play pivotal roles in early T-cell commitment, but also
at later stages of T-cell differentiation.5,6 These widely
expressed basic helix-loop-helix (bHLH) transcription fac-
tors cooperate with more tissue/lineage-restricted bHLH
proteins, such as LYL1 and SCL/TAL1, to form het-
erodimers that recognize a single 5’-CANNTG-3’ E-box
motif in their target promoters and regulatory elements.
As such, E-proteins regulate essential T-cell fate-determin-
ing factors including Rag1, Notch1, and the interleukin-7
receptor (Il7r). Only in the presence of the LIM-domain-
only (LMO) proteins and LMO-binding protein 1 (LDB1)
can bHLH heterodimers form larger multiprotein com-
plexes with a second bHLH heterodimer or with other
transcription factors, such as GATA proteins. LMO pro-
teins do not have intrinsic DNA-binding capacity and act
solely as essential scaffolding proteins for this multipro-
tein complex formation to bridge bipartite DNA motifs,
e.g. two E-boxes.7,8 
Activation of LMO1 and LMO2 genes, which results
from chromosomal aberrations such as translocations,
deletions or insertions in regulatory elements and promot-
ers, has been recurrently observed in patients with T-
ALL.9-11 Mouse models overexpressing Lmo1 and Lmo2
have demonstrated that both are potent oncogenic drivers
within the T-cell lineage.12,13 From 5 months of age, CD2-
LMO2tg mice spontaneously develop T-ALL with an
immature Lyl1+ expression profile.14 Unlike the thymus of
normal mice, which is continously replenished by progen-
itors from the bone marrow, the pre-leukemic thymus of
CD2-LMO2tg transgenic mice is self-sustaining.15,16 Similar
to other long-lived pre-leukemic stem cells, Lmo2-overex-
pressing thymocyte precursors retain the ability to differ-
entiate into the full spectrum of mature daughter cells, but
in addition, their stem cell properties allow clonal expan-
sion and subsequent acquisition of extra oncogenic driver
mutations, eventually leading to the onset of a fully trans-
formed leukemia. The pre-leukemic self-renewal capacity
of CD2-LMO2tg thymocytes is restricted to the CD4-CD8-
double-negative (DN) precursor T cells, more specifically
the CD4-CD8-CD44-CD25+ (DN3) subpopulation, and
strictly depends on the expression of the bHLH protein
LYL1.17
Zinc finger E-box binding homeobox transcription fac-
tors, ZEB1 and ZEB2, recognize a similar bipartite E-box
motif in their target promoters and regulatory elements.18,19
and as such regulate epithelial-to-mesenchymal transition
in the context of progression of solid tumors. In addition,
ZEB expression has been correlated with the acquisition
of cancer stem cell properties.20,21 Using loss-of-function
mouse models, it was previously demonstrated that both
ZEB proteins are also essential hematopoietic transcrip-
tion factors that play pivotal roles at various cell fate deci-
sion check points during hematopoiesis,22-24 including the
T-cell lineage.24-27 In addition, we recently showed that
Zeb2 overexpression can result in spontaneous develop-
ment of T-ALL with an immature Lyl1+ expression profile21
and a latency similar to that in CD2-LMO2tg/+ mice,14 sug-
gesting a common oncogenic mechanism of action. In
these mouse T-ALL, Zeb2 overexpression drives increased
expression of Il7r and aberrant activation of the IL7R-
JAK/STAT signaling pathway.21 Activating IL7R mutations
are also recurrently found in T-ALL patients.28
Interestingly, overexpression of gain-of-function mutant
variants of IL7R in p19(Arf)-/- mouse hematopoietic pro-
genitors resulted in a similar T-ALL formation with an
immature Lyl1+ expression profile, and high levels of
Lmo2.29 Based on the high Lmo2 expression in the IL7R
mutant tumors and phenotypic similarities with the CD2-
LMOtg mouse models, the authors suggested that T-ALL
initiation in both models might act via converging down-
stream signaling pathways that result in aberrant pre-
leukemic thymocyte self-renewal.29
In this study, we used transgenic mouse models to fur-
ther analyze the effects of Zeb1 and Zeb2 overexpression
on pre-leukemic T-cell differentiation. In contrast to Zeb1,
Zeb2 overexpression resulted in a partial cell-autonomous
differentiation delay and accumulation of a DN3 precursor
T-cell population, similar to what has been described in
the CD2-LMO2tg and IL7R mutant mouse models.
However, Zeb2 overexpression was not associated with
gain of pre-leukemic self-renewal capacity. Finally, using a
late-acting Cre line, we demonstrated that the early T-cell
differentiation defects are not essential for Zeb2-mediated
T-ALL initiation. Collectively, our data indicate that Zeb2
and Lmo2 drive a similar immature T-ALL subtype, but via
distinct oncogenic mechanisms. 
Methods 
Animal experimentation and handling
All experiments were performed according to the regulations
and guidelines of the ethics committee for care and use of labora-
tory animals of Ghent University and Monash University. 
For thymocyte transplantation experiments, donor thymi were
dissected under aseptic conditions. Single cells were prepared in
cold phosphate-buffered saline using a 40 μM cell strainer. Cell
concentrations were measured using a Burker cell counter cham-
ber. Thymocytes (1x 107) were intravenously injected into 6- to 10-
week old syngeneic Ly5.1 recipients that were irradiated with a
sublethal (550 Rad) dose 4 h before the transplant. One day before
and 14 days after the irradiation, mice were kept on neomycin
prophylaxis delivered at a dose of 1.7 mg/mL in acidified (pH 2.5)
drinking water.
Histology
Tissue samples were fixed in formalin, embedded in paraffin,
sectioned at 6 μm and stained with hematoxylin and eosin (H&E)
for histopathological examination as described in detail
elsewhere.21
Flow cytometry 
Both lobes of thymi were carefully dissected in 1 mL of cold
phosphate-buffered saline. Single-cell preparations were made
using a 40 μm cell strainer and cell numbers were quantified using
a Burker cell counting chamber. Cells were stained and analyzed
either by LSRII (BD Biosciences) or FACSAria II (BD Biosciences),
and FACSDiva or FlowJo software (BD Biosciences). Cell debris
and cell aggregates were gated out and dead cells were discarded
using the fixable Viability Dye eFluro506 (eBioscience). The anti-
bodies used for flow cytometry are listed in Online Supplementary
Table S1. Intracellular staining was done using a BD
Cytofix/Cytoperm kit (BD Bioscience) according to the manufac-
turer’s guidelines.
In vitro differentiation of fetal hematopoietic 
progenitors towards the T-cell lineage 
The differentiation experiments were performed as described
previously,30 plating 1 x 104 Lin-cKit+ hematopoietic progenitor cells
per 24-well plates of OP9-DL1 feeders in OP9 culture medium
supplemented with 5 ng/mL Flt3 ligand (R&D Systems) and 5
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ng/mL IL7 (or 1-0.2 ng/mL IL7 where indicated) (R&D Systems or
Peprotech). 
OP9-DL1 bone marrow stromal cells30 were maintained in
MEMalpha medium (Gibco), supplemented with 20% fetal
bovine serum (FCS; Hyclone), penicillin (100 U/mL)-streptomycin
(100 μg/mL), 2 mM L-glutamine (Gibco) and incubated at 37°C
with 7% CO2 and 95% humidity. E13.5 fetal liver cells were
stained with biotin-conjugated lineage cocktail antibodies [Gr-1
(Ly-6G & 6C), Ter119 (Ly-76), CD3ε, and B220 (CD45R);
eBioscience], PE-conjugated streptavidin (BD Biosciences, 1:200)
and CD117-APC (cKit, Immunosource, 1:200). Lin-cKit+ cells were
sorted using a FACSAria II machine (BD Biosciences) and
FACSDiva software. Dead cells were discarded via DAPI stain.
Real-time quantitative polymerase chain reactions
Total RNA was isolated using a RNeasy Plus Mini Kit (Qiagen).
cDNA was synthesized using the First Strand cDNA Synthesis Kit
(Roche) with oligo(dT) primers, starting from equal amounts of
RNA. Real-time quantitative polymerase chain reactions (qRT-
PCR) were performed using the LightCycler 480 SYBR Green I
Master (Roche), monitored on a LichtCycler 480 system (Roche)
and analyzed using qBase software from Biogazelle. Gene expres-
sion was standardized against the housekeeping genes β-actin,
glyceraldehyde-3-phosphate dehydrogenase (Gapdh), RPL13 and
TBP. All primers used are listed in Online Supplementary Table S2. 
Statistical analysis 
Data are presented as the mean ± standard deviation.
Comparisons between two data groups were performed using a
two-sided Student t-test. *P<0.05, **P<0.01, ***P<0.001 (vs. con-
trol).
Results 
Overexpression of Zeb2 but not Zeb1 induces 
spontaneous T-cell acute lymphoblastic leukemia 
in the mouse
We previously demonstrated that hematopoietic-specif-
ic overexpression of Zeb2 from the mouse ROSA26 locus
resulted in spontaneous T-ALL development.21 To docu-
ment the functional similarities and/or differences
between the two ZEB family members, we recently gen-
erated a similar Zeb1 conditional overexpression mouse
model using the same targeting strategies as previously
described for Zeb231 (Online Supplementary Figure S1A). In
these R26-Zeb1tg mice, an aminoterminal HA-tag Zeb1
cDNA, preceded by a floxed transcriptional stop cassette
and followed by an IRES-eGFP, was targeted to the
ROSA26 locus. The details on how these mice were gen-
erated have been submitted for publication elsewhere.
To compare the oncogenic potential of Zeb1 and Zeb2,
we crossed these newly generated R26-Zeb1tg mice to the
same Cre line as we used for the R26-Zeb2tg, the Tie2-cre,
which targets hematopoietic stem cells and their proge-
ny.32 This resulted in a moderate 2- to 3-fold overexpres-
sion of the total Zeb1 mRNA levels in the thymus, similar
to that in the R26-Zeb2tg mice (Online Supplementary Figure
S1B). These Tie2cre, R26-Zeb1tg/tg mice (henceforth
referred to as R26-Zeb1tg/tg) were born in normal Mendelian
ratios and no obvious phenotypes were observed at a
young age. While we previously reported that mice over-
expressing Tie2-cre, R26-Zeb2tg/tg (henceforth referred to as
R26-Zeb2tg/tg) spontaneously develop T-ALL starting from
the age of 5 months with a penetrance of 53% at 15
months of age, none of the R26-Zeb1tg/tg-overexpressing
mice (n=15) showed any signs of leukemia development
(Online Supplementary Figure S1C). These data indicate
that, in contrast to Zeb2, Zeb1 is not an oncogenic driver
of murine T-ALL.
Overexpression of Zeb2 results in thymic hypoplasia
and delayed T-cell development
Upon dissection, we noted that juvenile Zeb2-overex-
pressing mice, and not Zeb1-overexpressing mice, consis-
tently had smaller thymi compared to their littermate con-
trols. Except for a reduction of the medullary areas, no sig-
nificant changes were observed in thymus architecture
(Figure 1A). Next, detailed flow cytometric analysis was
performed on thymi of 8-week old R26-Zeb2tg versus con-
trol Cre-negative littermates. Upon Zeb2 overexpression, a
significant and dose-dependent decrease in total thymo-
cyte numbers was observed, associated with a significant
decrease in percentages and absolute numbers of mature
CD3+ and CD4+CD8+ double-positive Thy1+ cell popula-
tions, combined with increased percentages of the imma-
ture CD4-CD8- double negative (DN) Thy1+ population
(Figure 1B). These findings indicate that the thymic
hypoplasia in R26-Zeb2tg animals results from a partial
block or delay at an early stage during T-cell development.
Within the R26-Zeb2tg DN-gated cells, an abnormal popu-
lation of CD44- cells with intermediate levels of CD25
was observed, which was absent in the control thymus
(Figure 1C). These cells are Thy1+, CD49b-, B220- and
CD19-, confirming their T-cell lineage identity. Positive
staining for CD28 and intracellular TCRβ indicated that
these are early post-β-selected cells blocked or delayed at
the DN3 to DN4 transition, more specifically at DN3C. In
line with this notion, expression analysis of mouse and
human T-cell populations (Online Supplementary Figure S2)
revealed that endogenous ZEB2 levels are normally down-
regulated at this DN3-4 transition point.  
Notably, no T-cell differentiation block or delay was
seen in the Zeb1-overexpressing mice (Online
Supplementary Figure S1D), indicating that Zeb2 overex-
pression has effects on early T-cell differentiation that dif-
fer from those of Zeb1 overexpression.
The Zeb2-mediated differentiation delay 
is a hematopoietic cell-autonomous phenotype
As the Tie2-cre line also targets endothelial cells next to
hematopoietic cells, we wanted to exclude that paracrine
changes in the thymic microenvironment or architecture
cause the delay in T-cell differentiation in R26-Zeb2tgmice.
To this end, we performed in vitro T-cell differentiation
experiments with purified hematopoietic progenitor cells.
Sorted fetal liver hematopoietic progenitors (Lin-, cKit+)
from R26-Zeb2tg/tg or Cre-negative control E13.5 embryos
were seeded on OP9-DL1 bone marrow stromal cells that
express the Notch delta ligand-1,30 in the presence of 5
ng/mL Flt3 ligand and 5 ng/mL IL7. In vitro T-cell develop-
ment was monitored for 4 weeks. A significant delay in
T-cell development was already prominent within 1
week in the Zeb2-overexpressing co-cultures (Figure 2A),
exemplified by an increased frequency of cKit+ DN cells.
After 2 weeks, an increase of the DN3-like population
(CD3-,CD8-,CD44-,CD25int) and a concomitant decrease in
more mature cells (CD8+) were also observed, pointing to
a hematopoietic cell-autonomous delay or block in early
T-cell development upon Zeb2 overexpression (Figure 2A).
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After 4 weeks of culture, a large proportion of the R26-
Zeb2tg/+ cells remained DN3 with intermediate levels of
CD25, whereas all T cells had already differentiated
beyond the DN stage in the control cultures (Figure 2B). 
Zeb2-mediated increased interleukin-7 receptor 
signaling is involved in the T-cell differentiation delay
In our previous study, we demonstrated that ZEB2 direct-
ly regulates the Il7r promoter.33 Consequently, Zeb2-overex-
pressing T-ALL tumors and derived cell lines have high lev-
els of Il7rmRNA and are more responsive to exogenous IL7
levels. As downregulation of IL7 signaling, induced by the
pre-TCR signal, is crucial for normal transition of DN3 to
double-positive cells,34,35 we hypothesized that the Zeb2-
induced delay in T-cell differentiation is due to their inabil-
ity to downregulate Il7r. We therefore tested whether low-
ering the amount of recombinant IL7 in the culture medium
could overcome the observed delay in T-cell differentiation
in vitro. Indeed, reduction of the concentration of recombi-
nant IL7 from 5 ng/mL to 0.2 ng/mL rescued the delay in
differentiation, resulting in similar developmental kinetics
to that of the control co-cultures (Figure 2C). 
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Figure 1. Zeb2 overexpression results in a delay in T-cell development at the DN3 stage. (A) Hematoxylin & eosin-stained sections of paraffin-embedded thymi of
mice with and without mono- or bi-allelic ROSA26-mediated overexpression. (B) Flow cytometric analysis of thymi of Zeb2-overexpressing mice versus control litter-
mates. Absolute numbers of total thymocytes and percentages of CD3, CD4/8 double-positive (DP) and CD4/8 double-negative (DN) cell populations, DN1-4 and
DN3A-C subpopulations are shown. (C) Representative dot plots of CD4/8 DN populations stained with CD25 and CD44. In R26-Zeb2tg/+ and R26-Zeb2tg/tg thymi, an
abnormal DN3/4-like population is observed with intermediate CD25 levels (arrows). *P<0.05, **P<0.01, ***P<0.001 (vs control).
A
B C
ZEB2 overexpression does not induce pre-leukemic
thymocyte self-renewal
For the following reasons, we subsequently hypothe-
sized that thymocytes would also acquire pre-leukemic
self-renewal capacity upon Zeb2 overexpression, similar
to what has been observed in CD2-LMO2tg mice: (i) mice
with Zeb2 overexpression phenocopy the IL7R gain-of-
function mutant and CD2-LMOtg immature T-ALL mouse
models; (ii) ZEB2 and LMO2 bind similar bipartite E-box-
containing regulatory elements; (iii) ZEB2 expression has
been associated with acquisition of cancer stem cell prop-
erties in solid tumors; and (iv) Zeb2-overexpressing T-ALL
tumors and their derived cell lines have increased
leukemia-initiating potential. To test our hypothesis, we
S. Goossens et al.
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Figure 2. Zeb2-mediated T-cell differentiation delay is independent of the thymic mirco-environment. (A,B) Flow cytometric analysis of 1- and 2-week in vitro differ-
entiation cultures of E13.5 fetal liver hematopoietic progenitors on OP9-DL1 feeders. Percentages of DN1 (CD4/8- and CD44+, CD25-), DN2 (CD4/8- and CD44+,
CD25+), DN3 (CD4/8-, CD44-, CD25+) and post-DN3 (sCD3 or CD8+) populations show a significant delay in differentiation upon Zeb2 overexpression (A) and the pres-
ence of a cell population with intermediate CD25 expression even after 4 weeks of co-culture, as exemplified by a representative dot plot (B). (C) Lowering the con-
centration of recombinant interleukin 7 (IL7) in OP9-DL1 co-cultures partially rescues the delay in T-cell differentiation of R26-Zeb2tg/tg fetal liver hematopoietic pro-
genitors. Dot plots of representative cultures are shown as are the percentages of T-cell populations following addition of 5 ng/mL, 1 ng/mL and 0.2 ng/mL recom-
binant IL7. *P<0.05, **P<0.01, ***P<0.001 (vs. control).
A B
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backcrossed our R26-Zeb2tg model for ten generations to
pure C57BL/6 background (CD45.2+) mice to enable thy-
mocyte transplantation experiments. We injected 1x107
thymocytes from 8-week old R26-Zeb2tg/tg mice or litter-
mate controls into the tail vein of sublethally irradiated
syngeneic Ly5.1 (CD45.1+) recipients and used CD2-
LMO2tg thymocytes as the positive control. Via flow cyto-
metric analysis of CD45.1 versus CD45.2, we analyzed
how many of the donor versus recipient cells contributed
to the repopulation of the thymus at 4 and 6 weeks after
transplantation. Four weeks after transplantation, no
CD45.2+ wildtype thymocytes could be detected, while
varying low numbers of CD45.2+ Zeb2-overexpressing
thymocytes were consistently seen at this time point.
However, and in contrast to the CD2-LMO2tg thymocytes,
none of the Zeb2-overexpressing CD45.2 thymocytes
could be detected 6 weeks after transplantation (Figure 3).
These data demonstrate that Zeb2-overexpressing thymo-
cytes have prolonged survival capacity compared to that
of wildtype thymocytes, but that they do not have long-
term repopulation or self-renewal capacity.
The differentiation delay is not essential for 
the formation of Zeb2-mediated T-cell acute 
lymphoblastic leukemia
Finally, we wondered whether the observed T-cell dif-
ferentiation defect in Zeb2-overexpressing mice is essen-
tial for Zeb2-mediated T-ALL formation. To this end, we
crossed our R26-Zeb2tg mice with the CD4-cre, a late-act-
ing T-cell-specific Cre line that is only active after the
above-described DN3C block/delay (Figure 4A). No thy-
mocyte hypoplasia (Figure 4B), or early T-cell differentia-
tion defects could be observed in 8-week old CD4-cre,
R26-Zeb2tg/tg mice versus control littermates. Irrespective of
the lack of this early T-cell differentiation block, these
mice developed leukemia with approximately the same
latency and same penetrance (Figure 4C) as observed with
the early acting Tie2-cre line. Necropsy and histopatho-
logical examination was done on eight Tie2-cre,R26-
Zeb2tg/tg and five CD4-cre,R26-Zeb2tg/tg mice, as described in
our previous study.21 All leukemic mice were diagnosed
with precursor T-cell lymphoblastic leukemia. In general,
no immunophenotypic differences were observed
between the leukemias developing in the early- versus late-
acting Cre line. However, we noted that while all exam-
ined Tie2-cre,R26-Zeb2tg/tg mice had large mediastinal mass-
es, two out of the five CD4-cre,R26-Zeb2tg/tg mice had no
mediastinal mass. Furthermore, in these two leukemic
mice, the neoplastic cells appeared smaller. Since the phe-
notype in both models is not fully penetrant and we
observed large variation in leukemia onset and phenotype,
only a limited number (8 vs. 5) leukemic mice could be
analyzed fully and we cannot, therefore, draw strong con-
clusions from our observations.
Discussion
In various solid cancer types, ZEB expression has been
correlated with both poor prognosis and patients’ out-
comes. Indeed, ZEB1 and ZEB2 have been demonstrated
to increase cancer cell invasion and dissemination via the
regulation of epithelial-to-mesenchymal transition. In
addition, as for other regulators of epithelial-to-mesenchy-
mal transition, their expression has been associated with
the acquisition of cancer stem cell properties and therapy
resistance.36
It has been debated whether these structurally very
related family members compensate for each other or
whether they also have unique functions. The differences
in phenotypes between Zeb1 and Zeb2 knockout mice can
be explained by their complementary expression
patterns.37 Studies with compound Zeb1/Zeb2 double
knockouts have shown that they have at least partly over-
lapping, compensatory functions, but could not rule out
that they also have unique functions. Overexpression of
ZEB1/ZEB2 in various epithelial cancer cell lines catalyzed
similar phenotypes, with overlapping downstream tar-
gets.18,38,39 Mild differences between ZEB1/2-mediated
epithelial-to-mesenchymal transition were often reported,
but these could be attributed to differences in overexpres-
sion levels and/or the cellular context. Here, we provide
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Figure 3. Zeb2 overexpression does not induce pre-leukemic thymocyte self-renewal. Percentages of CD45.2+ donor-derived thymocytes that contribute to the repop-
ulation of sublethally irradiated syngeneic CD45.1+ recipients 4 or 6 weeks after transplantation. 
compelling evidence, for the first time, that ZEB1 and
ZEB2 can have unique functions. Overexpression in the
same cellular context, using the same targeting strategy,
expressed from the same endogenous promoter and in a
relevant in vivo setting, resulted in clearly distinct pheno-
types for ZEB1 and ZEB2. Using luciferase reporter con-
structs, others have previously shown that ZEB1 and
ZEB2 also have opposing effects on TGFβ1-mediated
repression of the 3TP and p21 promoter elements.40 At
that time, the authors hypothesized that these seemingly
opposite effects were mediated by the putative differen-
tial recruitment of ZEB1/2-specific co-activators/repres-
sors, such as p300 and P/CAF. This differential recruitment
of co-factors may specifically switch ZEB1 from a repres-
sor into an activator. However, others have counteracted
this hypothesis by demonstrating that ZEB1 and ZEB2 are
equally potent at binding p300 and P/CAF. Furthermore,
although the extensive list of ZEB-interacting proteins is
growing continuously, no unique interactors have been
documented thus far. In this study, we prove that the dis-
tinct phenotypes observed are not due to differences in
cellular contexts or mRNA (over)expression levels.
Unfortunately, no instruments are available to test
whether these similar mRNA levels also translate into
similar transgene protein levels. Cell-context-dependent
differences in post-translational regulation of both ZEB
family members may result in more or less of the ZEB1/2
transgene protein and may explain the phenotypic differ-
ences observed between the two models. 
It is important to mention here that although early T-cell
development of R26-Zeb1tg mice is normal and these mice
do not spontaneously develop leukemia, this does not
exclude that other hematopoietic lineages are not affected
by the Zeb1 overexpression.
In the context of T-cell malignancies, ZEB1 and ZEB2
seem to act in an opposite manner. A tumor suppressor
role for ZEB1 in T-cell leukemias/lymphomas has previ-
ously been suggested,41 based on its expression, the muta-
S. Goossens et al.
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Figure 4. Zeb2-mediated T-cell differentiation delay is not essential for Zeb2-induced T-cell acute lymphoblastic leukemia formation. (A) Flow cytometric analysis
of the percentages of eGFP+ cells in DN3 versus DP demonstrating differential Cre activity between the early-acting Tie2-cre line and the late-acting CD4-cre line in
early T-cell precursors. (B) Flow cytometric analysis of thymi of Zeb2-overexpressing mice versus control littermates upon intercross with either the Tie2-cre or CD4-
cre line. Absolute numbers of total thymocytes and percentages of CD3, CD4/8 double-positive (DP) and CD4/8 double-negative (DN) cell populations demonstrate
that there is no differentiation delay in the late-acting CD4-cre line. (C) Kaplan-Meier curve for leukemia-free survival of CD4-cre, R26-Zeb2tg/tg (n=18) versus Tie2-
cre, R26-Zeb2tg/tg (n=21) mice. *P<0.05, **P<0.01, ***P<0.001 (vs. control); NS, not significant.
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tions found in patients and the observed spontaneous T-
cell lymphoma development in a mouse model expressing
a carboxyterminal truncated form of ZEB1. This is in con-
trast with the oncogenic role we have described for Zeb2 in
T-ALL.21 In this study, we demonstrated that pre-leukemic
T-cell differentiation is also affected by Zeb2 overexpres-
sion. Maintenance of Zeb2 expression results in a partial
differentiation block or delay at an early DN3C stage, coin-
ciding with the T-cell developmental stage at which Zeb2
expression is normally downregulated in mice, as well as in
humans. This delay could be partially rescued by decreas-
ing IL7R pathway activation, suggesting that the delay is
caused by an inability of the Zeb2-overexpressing thymo-
cytes to downregulate IL7R expression. Interestingly, other
mouse models have shown a similar block in T-cell differ-
entiation at this key transition point, including mice that
overexpress the IL7r.35,42CD2-LMO2tg animals accumulate a
similar aberrant DN3 population at a young age. Notably,
our detailed flow cytometric analysis revealed that LMO2-
overexpressing cells are delayed slightly earlier in T-cell dif-
ferentiation compared to the Zeb2-overexpressing thymo-
cytes, at the DN3A stage, and before T-cell rearrangement
(data not shown). 
As ZEB have been previously associated with the acqui-
sition of cancer stem cell properties, we hypothesized that
the cause of spontaneous T-ALL formation in R26-Zeb2tg
could be due to acquired self-renewal of pre-leukemic thy-
mocytes, as previously demonstrated for LMO2. This was
supported by the fact that both proteins bind similar reg-
ulatory elements, and that both factors can drive murine
T-ALL development with a similar immature expression
profile and increased stem cell properties. Nevertheless,
using thymocyte transplantation experiments, we demon-
strated that R26-Zeb2tg thymocytes are not able to recon-
stitute an irradiated thymus and therefore have no pre-
leukemic self-renewal capacity. These data indicate differ-
ent oncogenic mechanism for ZEB2 and LMO2. Upon
transplantation, we observed that the survival of R26-
Zeb2tg thymocytes was longer than that of wildtype thy-
mocytes, with this difference most probably being associ-
ated with increased IL7R signaling. Whether the increase
in Il7r expression is involved in tumor initiation in R26-
Zeb2tg animals remains to be determined.  
Finally, we used a late-acting CD4-Cre line to show that
Zeb2 could also transform thymic precursor cells at later
stages during their development, suggesting that the delay
at the DN3C stage is not essential for leukemic transfor-
mation. Interestingly, a forward genetic screening used the
same CD4-Cre line to activate the “sleeping beauty trans-
posase” and induce oncogenic transformation specifically
at later stages of T-cell development, which resulted in T-
ALL with an immature expression profile.43 These data
indicate that cases of immature murine T-ALL can also
originate in cells beyond the DN stage. Furthermore, our
data suggest that a Zeb2-transformed T-ALL with an
immature/stem cell expression profile can originate from a
more differentiated cell without self-renewal capacity.
In summary, we conclude that multiple oncogenes such
as ZEB2 and LMO2 are able to induce subtypes of imma-
ture murine T-ALL via distinct oncogenic mechanisms of
action. In addition, Zeb2 can also drive T-cell transforma-
tion in more differentiated T-cell precursor cells with sim-
ilar kinetics. 
Acknowledgments 
This work was supported by the Australian NHMRC (grant
1047995 to JJH), the Worldwide Cancer Research Fund, the
Swiss Bridge Foundation, Stand Up Against Cancer Fund, the
Ghent University Special Research Fund and the Fund for
Scientific Research-Flanders.
Oncogenic mechanisms of ZEB1 and LM02 in T-ALL
haematologica | 2019; 104(8) 1615
References
1. Rothenberg EV. T cell lineage commitment:
identity and renunciation. J Immunol.
2011;186(12):6649-6655.
2. Morris GP, Allen PM. How the TCR bal-
ances sensitivity and specificity for the
recognition of self and pathogens. Nat
Immunol. 2012;13(2):121-128.
3. Meijerink JP. Genetic rearrangements in rela-
tion to immunophenotype and outcome in
T-cell acute lymphoblastic leukaemia. Best
Pract Res Clin Haematol. 2010;23(3):307-
318.
4. Van Vlierberghe P, Ferrando A. The molecu-
lar basis of T cell acute lymphoblastic
leukemia. J Clin Invest. 2012;122(10):3398-
3406.
5. Engel I, Murre C. The function of E- and Id
proteins in lymphocyte development. Nat
Rev Immunol. 2001;1(3):193-199.
6. Wang LH, Baker NE. E Proteins and ID pro-
teins: helix-loop-helix partners in develop-
ment and disease. Dev Cell. 2015;35(3):269-
280.
7. Wadman I, Li J, Bash RO, et al. Specific in
vivo association between the bHLH and
LIM proteins implicated in human T cell
leukemia. EMBO J. 1994;13(20):4831-4839.
8. Wadman IA, Osada H, Grutz GG, et al. The
LIM-only protein Lmo2 is a bridging mole-
cule assembling an erythroid, DNA-binding
complex which includes the TAL1, E47,
GATA-1 and Ldb1/NLI proteins. EMBO J.
1997;16(11):3145-3157.
9. Boehm T, Foroni L, Kaneko Y, Perutz MF,
Rabbitts TH. The rhombotin family of cys-
teine-rich LIM-domain oncogenes: distinct
members are involved in T-cell transloca-
tions to human chromosomes 11p15 and
11p13. Proc Natl Acad Sci U S A.
1991;88(10):4367-4371.
10. Van Vlierberghe P, van Grotel M, Beverloo
HB, et al. The cryptic chromosomal deletion
del(11)(p12p13) as a new activation mecha-
nism of LMO2 in pediatric T-cell acute lym-
phoblastic leukemia. Blood. 2006;108(10):
3520-3529.
11. Goossens S, Van Vlierberghe P. Novel onco-
genic noncoding mutations in T-ALL. Blood.
2017;129(24):3140-3142.
12. Fisch P, Boehm T, Lavenir I, et al. T-cell acute
lymphoblastic lymphoma induced in trans-
genic mice by the RBTN1 and RBTN2 LIM-
domain genes. Oncogene. 1992;7(12):2389-
2397.
13. Neale GA, Rehg JE, Goorha RM. Ectopic
expression of rhombotin-2 causes selective
expansion of CD4-CD8- lymphocytes in the
thymus and T-cell tumors in transgenic
mice. Blood. 1995;86(8):3060-3071.
14. Smith S, Tripathi R, Goodings C, et al. LIM
domain only-2 (LMO2) induces T-cell
leukemia by two distinct pathways. PloS
One. 2014;9(1):e85883.
15. McCormack MP, Young LF, Vasudevan S, et
al. The Lmo2 oncogene initiates leukemia in
mice by inducing thymocyte self-renewal.
Science. 2010;327(5967):879-883.
16. Cleveland SM, Smith S, Tripathi R, et al.
Lmo2 induces hematopoietic stem cell-like
features in T-cell progenitor cells prior to
leukemia. Stem Cells. 2013;31(5):882-894.
17. McCormack MP, Shields BJ, Jackson JT, et al.
Requirement for Lyl1 in a model of Lmo2-
driven early T-cell precursor ALL. Blood.
2013;122(12):2093-2103.
18. Comijn J, Berx G, Vermassen P, et al. The
two-handed E box binding zinc finger pro-
tein SIP1 downregulates E-cadherin and
induces invasion. Mol Cell. 2001;7(6):1267-
1278.
19. Remacle JE, Kraft H, Lerchner W, et al. New
mode of DNA binding of multi-zinc finger
transcription factors: delta EF1 family mem-
bers bind with two hands to two target
sites. EMBO J. 1999;18(18):5073-5084.
20. Wellner U, Schubert J, Burk UC, et al. The
EMT-activator ZEB1 promotes tumorigenic-
ity by repressing stemness-inhibiting
microRNAs. Nat Cell Biol. 2009;11(12):
1487-1495.
21. Goossens S, Radaelli E, Blanchet O, et al.
ZEB2 drives immature T-cell lymphoblastic
leukaemia development via enhanced
tumour-initiating potential and IL-7 receptor
signalling. Nat Commun. 2015;6:5794.
22. Goossens S, Janzen V, Bartunkova S, et al.
The EMT regulator Zeb2/Sip1 is essential
for murine embryonic hematopoietic
stem/progenitor cell differentiation and
mobilization. Blood. 2011;117(21):5620-
5630.
23. Li J, Riedt T, Goossens S, et al. The EMT
transcription factor Zeb2 controls adult
murine hematopoietic differentiation by
regulating cytokine signaling. Blood.
2017;129(4):460-472.
24. Higashi Y, Moribe H, Takagi T, et al.
Impairment of T cell development in delta
EF1 mutant mice. J Exp Med. 1997;185(8):
1467-1479.
25. Omilusik KD, Best JA, Yu BF, et al.
Transcriptional repressor ZEB2 promotes
terminal differentiation of CD8(+) effector
and memory T cell populations during infec-
tion. J Exp Med. 2015;212(12):2027-2039.
26. Dominguez CX, Amezquita RA, Guan TX,
et al. The transcription factors ZEB2 and T-
bet cooperate to program cytotoxic T cell
terminal differentiation in response to
LCMV viral infection. J Exp Med.
2015;212(12):2041-2056.
27. Guan T, Dominguez CX, Amezquita RA, et
al. ZEB1, ZEB2, and the miR-200 family
form a counterregulatory network to regu-
late CD8(+) T cell fates. J Exp Med.
2018;215(4):1153-1168.
28. Zhang J, Ding L, Holmfeldt L, et al. The
genetic basis of early T-cell precursor acute
lymphoblastic leukaemia. Nature. 2012;481
(7380):157-163.
29. Treanor LM, Zhou S, Janke L, et al.
Interleukin-7 receptor mutants initiate early
T cell precursor leukemia in murine thymo-
cyte progenitors with multipotent potential.
J Exp Med. 2014;211(4):701-713.
30. Schmitt TM, de Pooter RF, Gronski MA,
Cho SK, Ohashi PS, Zuniga-Pflucker JC.
Induction of T cell development and estab-
lishment of T cell competence from embry-
onic stem cells differentiated in vitro. Nat
Immunol. 2004;5(4):410-417.
31. Tatari MN, De Craene B, Soen B, et al.
ZEB2-transgene expression in the epidermis
compromises the integrity of the epidermal
barrier through the repression of different
tight junction proteins. Cell Mol Life Sci.
2014;71(18):3599-3609.
32. Kisanuki YY, Hammer RE, Miyazaki J,
Williams SC, Richardson JA, Yanagisawa M.
Tie2-Cre transgenic mice: a new model for
endothelial cell-lineage analysis in vivo. Dev
Biol. 2001;230(2):230-242.
33. Goossens S, Radaelli E, Blanchet O, et al.
ZEB2 drives immature T-cell lymphoblastic
leukaemia development via enhanced
tumour-initiating potential and IL-7 receptor
signalling. Nat Commun. 2015;6:5794.
34. El Kassar N, Lucas PJ, Klug DB, et al. A dose
effect of IL-7 on thymocyte development.
Blood. 2004;104(5):1419-1427.
35. Munitic I, Williams JA, Yang Y, et al.
Dynamic regulation of IL-7 receptor expres-
sion is required for normal thymopoiesis.
Blood. 2004;104(13):4165-4172.
36. Goossens S, Vandamme N, Van Vlierberghe
P, Berx G. EMT transcription factors in can-
cer development re-evaluated: beyond EMT
and MET. Biochim Biophys Acta Rev
Cancer. 2017;1868(2):584-591.
37. Miyoshi T, Maruhashi M, Van De Putte T,
Kondoh H, Huylebroeck D, Higashi Y.
Complementary expression pattern of
Zfhx1 genes Sip1 and deltaEF1 in the mouse
embryo and their genetic interaction
revealed by compound mutants. Dev Dyn.
2006;235(7):1941-1952.
38. Vandewalle C, Comijn J, De Craene B, et al.
SIP1/ZEB2 induces EMT by repressing genes
of different epithelial cell-cell junctions.
Nucleic Acids Res. 2005;33(20):6566-6578.
39. Eger A, Aigner K, Sonderegger S, et al.
DeltaEF1 is a transcriptional repressor of E-
cadherin and regulates epithelial plasticity in
breast cancer cells. Oncogene. 2005;24(14):
2375-2385.
40. Postigo AA. Opposing functions of ZEB pro-
teins in the regulation of the TGF beta/BMP
signaling pathway. EMBO J. 2003;22(10):
2443-2452.
41. Hidaka T, Nakahata S, Hatakeyama K, et al.
Down-regulation of TCF8 is involved in the
leukemogenesis of adult T-cell
leukemia/lymphoma. Blood. 2008;112(2):
383-393.
42. Trigueros C, Hozumi K, Silva-Santos B, et al.
Pre-TCR signaling regulates IL-7 receptor
alpha expression promoting thymocyte sur-
vival at the transition from the double-nega-
tive to double-positive stage. Eur J Immunol.
2003;33(7):1968-1977.
43.  Berquam-Vrieze KE, Nannapaneni K, Brett
BT, et al. Cell of origin strongly influences
genetic selection in a mouse model of T-
ALL. Blood, 2011;118(17):4646-4656.
S. Goossens et al.
1616 haematologica | 2019; 104(8)
